Table 3 Unadjusted and adjusted costs, SF6D utility scores and QALYs among DESIR patients satisfying selected criteria sets
|  | Canada n = 169 | France n = 197 | UK n = 86 | Germany n = 175 | Hong Kong n = 61 | |||||
|---|---|---|---|---|---|---|---|---|---|---|
Anti-TNF non-user (n = 98) | Anti-TNF user (n = 71) | Anti-TNF non-user (n = 117) | Anti-TNF user (n = 80) | Anti-TNF non-user (n = 46) | Anti-TNF user (n = 40) | Anti-TNF non-user (n = 108) | Anti-TNF user (n = 67) | Anti-TNF non-user (n = 29) | Anti-TNF user (n = 32) | |
Unadjusted | ||||||||||
 Total costs (Mean ± SD) | 1981 ± 2812 | 15,448 ± 6155 | 2117 ± 2976 | 15,311 ± 5801 | 1426 ± 1852 | 16,475 ± 7506 | 2044 ± 3351 | 15,339 ± 6453 | 1697 ± 2447 | 15,132 ± 6548 |
 Health Practitioner | 655 ± 745 | 896 ± 772 | 640 ± 720 | 1000 ± 939 | 440 ± 573 | 971 ± 1034 | 605 ± 750 | 953 ± 1013 | 472 ± 722 | 835 ± 682 |
 Hospital | 532 ± 1289 | 710 ± 2010 | 615 ± 1505 | 678 ± 1913 | 530 ± 1326 | 646 ± 1394 | 454 ± 1090 | 731 ± 2036 | 695 ± 1541 | 591 ± 1184 |
 Medical Act | 178 ± 238 | 399 ± 362 | 185 ± 247 | 396 ± 352 | 155 ± 239 | 449 ± 417 | 154 ± 228 | 386 ± 313 | 162 ± 330 | 433 ± 388 |
 Medication | 149 ± 135 | 12,511 ± 5252 | 143 ± 132 | 12,364 ± 5114 | 126 ± 100 | 12,742 ± 5844 | 145 ± 125 | 12,409 ± 5497 | 138 ± 120 | 11,981 ± 4977 |
 Productivity | 467 ± 1893 | 932 ± 2796 | 534 ± 1987 | 872 ± 2411 | 176 ± 526 | 1667 ± 4059 | 687 ± 2661 | 859 ± 2776 | 231 ± 672 | 1292 ± 3271 |
 Total costs: Med (IQR) | 913 (362, 2343) | 14,172 (12,741, 17,495) | 920 (364, 2343) | 14,293 (12,806, 17,537) | 839 (326, 1621) | 14,963 (13,110, 18,742) | 865 (323, 2092) | 14,111 (12,825, 16,356) | 809 (298, 1681) | 14,404 (12,579, 17,222) |
SF6D (Mean ± SD) | ||||||||||
 Index | 0.579 ± 0.101 | 0.532 ± 0.078 | 0.579 ± 0.098 | 0.533 ± 0.075 | 0.602 ± 0.088 | 0.528 ± 0.074 | 0.594 ± 0.105 | 0.536 ± 0.079 | 0.594 ± 0.078 | 0.531 ± 0.073 |
 6 M after index visit | 0.645 ± 0.108 | 0.644 ± 0.130 | 0.638 ± 0.105 | 0.635 ± 0.128 | 0.644 ± 0.103 | 0.630 ± 0.130 | 0.650 ± 0.111 | 0.652 ± 0.132 | 0.609 ± 0.094 | 0.624 ± 0.128 |
 12 M after INDEX VISit | 0.647 ± 0.118 | 0.620 ± 0.123 | 0.639 ± 0.115 | 0.612 ± 0.122 | 0.639 ± 0.108 | 0.609 ± 0.112 | 0.646 ± 0.124 | 0.632 ± 0.123 | 0.633 ± 0.099 | 0.595 ± 0.107 |
 Total QALY (Mean ± SD) | 0.63 ± 0.09 | 0.61 ± 0.10 | 0.62 ± 0.09 | 0.60 ± 0.10 | 0.63 ± 0.08 | 0.60 ± 0.10 | 0.63 ± 0.09 | 0.62 ± 0.10 | 0.61 ± 0.07 | 0.59 ± 0.09 |
Adjusted (Mean ± SE) | ||||||||||
 Total costs | 1703 ± 366 | 15,741 ± 802 | 1763 ± 347 | 15,773 ± 687 | 756 ± 644 | 16,952 ± 1160 | 1874 ± 408 | 15,617 ± 852 | 722 ± 946 | 15,764 ± 1229 |
 Total QALY | 0.61 ± 0.01 | 0.63 ± 0.01 | 0.61 ± 0.01 | 0.62 ± 0.01 | 0.61 ± 0.01 | 0.63 ± 0.02 | 0.62 ± 0.01 | 0.64 ± 0.01 | 0.59 ± 0.02 | 0.62 ± 0.02 |